KMUP-4 

KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterases (PDEs) and activating K⁺ channels. KMUP-4 can be used in the study of cardiovascular diseases^[1].

KMUP-4 (1 nM-100 μM) produces concentration-dependent vasorelaxant effects on deendothelial aortas (E2) (pEC₅₀=5.94) and intact endothelial aortas (E+) (PEC₅₀=6.45), indicating that the vasodilatory effect of KMUP-4 is partially dependent on endothelial cells^[1].
KMUP-4 (10 μM) shows 56%, 33% and 15% inhibitory activity against PDE3, PDE4 and PDE5 in HUVECs^[1].
KMUP-4 (0.1 μM, 18 h) increases significantly the expression of eNOS protein in HUVECs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

413.43

C₁₉H₂₃N₇O₄

864873-81-4

O=C1C2=C(N(C(N1C)=O)C)N=CN2CCN3CCN(CC3)C4=C(C=CC=C4)[N+]([O-])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. BN Wu, et al. Aortic Smooth Muscle Relaxants KMUP-3 and KMUP-4, Two Nitrophenylpiperazine Derivatives of Xanthine, Display cGMP-Enhancing Activity: Roles of Endothelium, Phosphodiesterase, and K:+: Channel. Journal of cardiovascular pharmacology 46.5 (2005): 600-608.  [Content Brief]